Somnolence

New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT

Retrieved on: 
Thursday, March 7, 2024

First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.

Key Points: 
  • First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.
  • Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses.
  • PETV's SPRYNG™ with OsteoCushion Technology is a "Game Changer" medical device that successfully treats pets and gives owners options beyond surgeries.
  • New to The Street airs TV Host Jane King's interview with VRM BioLogik® Group's (VRM) Ken Bellamy, Founder and President .

New York Film Academy Musical Theatre Students to Give an Unforgettable Performance in the Musical "[title of show]"

Retrieved on: 
Wednesday, March 6, 2024

Additionally, musical theatre is offered as a concentration as part of the NYFA's Bachelor of Fine Arts in Entertainment Media .

Key Points: 
  • Additionally, musical theatre is offered as a concentration as part of the NYFA's Bachelor of Fine Arts in Entertainment Media .
  • Originally published as a book, “[title of show]” was written by Hunter Bell and adapted for the stage by Jeff Bowen.
  • The 90-minute musical follows the story of Jeff and Hunter, two writers who learn of a new musical theatre festival with a fast-approaching deadline.
  • “Our musical theatre students never cease to amaze me with their commitment to our productions - and “[title of show]’ is no exception.

Sleep experts call for end of seasonal time changes ahead of ’springing forward‘

Retrieved on: 
Monday, February 26, 2024

The American Academy of Sleep Medicine urges policymakers to prioritize the well-being of individuals by abolishing seasonal time changes in favor of permanent standard time.

Key Points: 
  • The American Academy of Sleep Medicine urges policymakers to prioritize the well-being of individuals by abolishing seasonal time changes in favor of permanent standard time.
  • The AASM is joined by members of the Coalition for Permanent Standard Time in this effort to "ditch daylight saving time” and restore permanent standard time.
  • Set clocks ahead one hour in the early evening on March 9 and then go to sleep at your normal bedtime that evening.
  • For more information about daylight saving time and to find additional resources from the AASM about sleep disorders, treatments and sleep health, visit SleepEducation.org .

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Retrieved on: 
Thursday, February 22, 2024

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.
  • The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model.
  • The study demonstrated full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg.
  • “The preclinical data published in Drug Development Research demonstrate BAER-101’s ability to fully suppress seizures in the GAERS model, a translational animal model for anti-seizure drug development with a documented high predictability of response in humans.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Daylight Savings Increases Risk of Drowsy Driving

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 7, 2024 /PRNewswire/ -- Daylight savings time begins Sunday morning and with it comes an increased risk of drowsy driving. Traffic safety experts cite drowsiness as a significant factor in crashes nationwide that kill more than 5,000 people on our roads and highways every year.

Key Points: 
  • National Road Safety Foundation offers tips to stay alert at the wheel; Study shows 1/3 of drivers admit to falling asleep at the wheel
    NEW YORK, March 7, 2024 /PRNewswire/ -- Daylight savings time begins Sunday morning and with it comes an increased risk of drowsy driving.
  • "Drowsy driving can be as dangerous as drinking and driving," said Michelle Anderson of The National Road Safety Foundation, a non-profit organization that produces and distributes free driver safety education materials.
  • Drowsy driving is a factor in more than 300,000 crashes every year, causing 109,000 injuries and more than $30 billion in losses, according to the National Highway Traffic Safety Administration.
  • NRSF programs, which are free, deal with distracted driving, speed and aggression, impaired driving, drowsy driving, driver proficiency and pedestrian safety.

Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") launches MOTPOLY XR™ (lacosamide) extended-release capsules C-V, the first, and only once-daily formulation of lacosamide

Retrieved on: 
Monday, February 26, 2024

MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

Key Points: 
  • MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
  • MOTPOLY XR is bioequivalent to Vimpat® (lacosamide) film-coated tablets, C-V and provides a new once-daily option at equivalent doses.
  • "MOTPOLY XR marks a major milestone for Aucta as our 1st branded pharmaceutical product to enter the US market.
  • To report SUSPECTED ADVERSE REACTIONS, contact Aucta Pharmaceuticals, Inc. at 1-800-655-9902 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

Retrieved on: 
Friday, February 16, 2024

New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:

Key Points: 
  • New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:
    2).
  • Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia.
  • Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success.
  • Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients.

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Retrieved on: 
Thursday, February 15, 2024

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.

Key Points: 
  • BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.
  • In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist,” the authors describe the development of CVN766 to be over 1,000-fold more selective for the orexin 1 receptor (Ox1R) than the orexin 2 receptor (Ox2R).
  • Dysfunction of this target, Ox1R, is implicated in psychiatric disorders, such as schizophrenia, addictions (including food), and anxieties.
  • “CVN766 has demonstrated high brain permeability, prolonged receptor occupancy, and a pharmacokinetic and safety profile suitable for clinical evaluation across various psychiatric indications,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.

Santé's Expert Commentary on the Danger of Tianeptine or "Gas Station Heroin"

Retrieved on: 
Monday, February 12, 2024

ARGYLE, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- The U.S. Food and Drug Administration (FDA) recently issued a new and urgent warning about using any products, such as Neptune's Fix, that contain tianeptine. They sent a letter on January 11, 2024 to convenience stores, gas stations, vape/smoke shops and other companies advising the retailers to stop selling any tianeptine-containing products. In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.

Key Points: 
  • In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.
  • There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.
  • In fact, tianeptine products are being touted "with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.

  • "There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.